Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TICH-3 tranexamic acid for hyperacute spontaneous intracerebral haemorrhage
2022-500587-35-01Phase 3Authorised
- Sponsor
- University of Nottingham
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in intracerebral hemorrhage (ICH) and stroke comparing Cyklokapron with Placebo comparator (2 arms). Primary endpoint: Mortality at 28 days. Planned start Jul 2023; status: authorised.
02
Drugs
tranexamic acid
03
Conditions
intracerebral hemorrhage (ICH)stroke
Beyond the preview
Go deeper on 2022-500587-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500587-35-01.